CEL-SCI (FRA:LSR) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LSR CEL-SCI Corp FRA:LSR
31 GF Score
Price €1.10
! 2 Warning Signs
View Full Analysis

What is CEL-SCI Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:LSR
31GF Score
CEL-SCI Corp FRA:LSR
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CEL-SCI Business Description

Other Exchanges CVM:USA
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
31GF Score

Get the complete analysis for FRA:LSR

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.10
Price